EVIDENCE LIBRARY
Nitazenes in Dried Blood Spots: Storage Findings Need Compound-Specific Interpretation
A four-nitazene stability study illustrates why storage conclusions depend on concentration, temperature, matrix, and the measured endpoint.
Dried blood spots can be useful specimens, but drying blood does not establish stability for every analyte. A conclusion about storage should identify the compound, concentration, collection material, temperature, and elapsed interval to which it applies.
Nitazene research provides a useful example of why broad statements such as “refrigeration preserves the sample” or “dried spots are stable at room temperature” require a defined evidentiary basis.
What the four-compound study found
A 2024 LC–HRMS study examined etazene, flunitazene, isotonitazene, and protonitazene in dried blood spots over 30 days. At an initial 1 ng/mL, all four were below the reported 0.5 ng/mL LOQ after 30 days at room temperature. At 5 ng/mL, their reported remaining proportions at room temperature differed: 44%, 99%, 95%, and 90%, respectively. The authors also observed substantial variability. Peer-reviewed experimental study, November 17, 2024; full-text results consulted, DOI: 10.3390/ijms252212332.
Those findings concern the study's dried-spot conditions. They do not validate the same storage interval for liquid blood, every nitazene analogue, or every collection device.
Below quantification is not the same as chemically absent
When a stored specimen falls below the LOQ, the immediate conclusion is that the method cannot quantify it according to that limit. Whether it remains identifiable depends on separate identification criteria and available signal. Reports should preserve that distinction.
The numerical starting concentration also matters. Similar absolute changes can have very different consequences near the reporting limit and well above it. A stability assessment performed only at relatively high concentrations may leave uncertainty at the low concentrations encountered in a particular case.
For validation planning, include concentrations relevant to the intended reporting range and define the allowable change in advance. Record variation among replicates rather than summarizing the experiment with a single reassuring average.
Specimen handling is part of the analytical system
Collection volume, drying interval, spot uniformity, punch location, packaging, and storage history are useful records to preserve. If the procedure uses only part of a spot, establish how that portion represents the deposited blood and whether the method addressed the resulting variability.
Ask when the internal standard was added and what it can correct. An internal standard introduced during extraction does not necessarily account for events that occurred while the blood was drying or stored.
For a case specimen, distinguish documented conditions from assumed ones. A notation that a package was received intact does not itself describe the temperature throughout transportation or the interval before drying. Conversely, missing documentation establishes uncertainty, not proof that degradation occurred.
What a later negative can support
A delayed negative result should be evaluated against the relevant method and stability evidence. If the compound was originally present near the reporting limit, the available studies may raise a meaningful question about whether it remained detectable. The appropriate conclusion depends on the actual conditions, not merely on the age of the specimen.
Avoid converting a published percentage remaining into a case-specific original concentration without validated applicability. A study average is not a reconstruction of an individual specimen's history.
The practical response is prompt, appropriately validated analysis; documented storage; retained data; and candid reporting of limitations. The result may still be informative even when a precise reconstruction is impossible. Related background is available in dried blood spot toxicology and specimen stability.